Sentences with phrase «allografts in»

Balb / c third - party allografts were acutely rejected in chimeric animals, as were control MRL allografts in non-chimeric animals.

Allogenic allografts in chimeric mice were harvested on either day 40 or day 100 - post transplantation.

Studies in CD8 knockout (KO) and perforin KO mice demonstrated that CD8 + cytotoxic T lymphocytes (CTL) are unnecessary for the rejection of corneal allografts in mice (8, 9).

By contrast, adoptive transfer of CD8 − spleens cells from similar donors resulted in the rejection of corneal allografts in almost half of the hosts.

Histopathological examination of rejected corneal allografts in CD4 KO mice revealed a mixed inflammatory infiltrate containing large numbers of neutrophils and mononuclear cells, which was indistinguishable from the infiltrate seen in rejected corneal allografts in wild - type mice (data not shown).

The present demonstration of T cell - mediated apoptosis of allogeneic corneal cells from CD4 KO mice is consistent with previous findings, which noted the presence of apoptotic keratocytes and corneal endothelial cells in rejected corneal allografts in humans and rats respectively (5, 32).

«The use of 15 - mg / kg ATLG was associated with statistically improved event - free survival in the subgroups of children with acute leukemia or with acute lymphoblastic leukemia, which represents the more frequent indication for an allograft in hematologic malignancies of childhood.»

Fresh hypothermically stored amniotic allograft in the treatment of chronic nonhealing ulcers: a prospective case series - Dove Medical Press

Initial Experience with Tricortical Iliac Crest Bone Graft and Human Amniotic Allograft in Evans Calcaneal Osteotomy

Not exact matches

A study in 2011 looking at more than 645 ACL surgeries found that in patients between the ages of 10 ««19, allograft tissue had a four times higher failure rate than using your own tissue.

This may entail making small holes in the bone to allow new cartilage to grow (microfracture), taking cartilage from another part of the athlete's knee and transplanting it into the defect (osteochondral autograft transfer), taking cartilage cells from the knee and then having them grown in a lab for later re-implantation (autologous chondrocyte implantation), or taking cartilage from a person who has passed away and placing it in the defect (osteochondral allograft transfer).

The study, «Optimizing Femoral - head Osteochondral Allograft Transplantation in a Preclinical Model,» recently was published in the Journal of Orthopaedic Translation.

The rate of early allograft dysfunction — a serious and potentially deadly complication of transplantation — occurred in only 10 % of machine - stored liver recipients, versus 30 % of those allocated ice - stored ones.

Using an approach developed at Maisonneuve - Rosemont, consisting of an autograft to reduce tumour mass followed by a family allograft three to four months later to clean the bone marrow of myeloma cells with immune cells from a family donor (immunotherapy), the study resulted in a total cure rate of 41 %, a record level using this strategy.

Moreover, patients in complete remission six months after the allograft had a relapse - free survival rate of 60 %.

Overall, the autograft strategy followed by allograft resulted in relapse - free survival rates of 20 - 25 % in the long term.

Moreover, in the same study, the mortality rate associated with this treatment over ten years was 10 %, an extremely low rate following a family donor allograft.

«Our study results highlight that in a young athletic population, allografts (tissue harvested from a donor) fail more frequently than using autografts (tissue harvested from the patient),» said Craig R. Bottoni, MD, lead author from Tripler Army Medical Center in Honolulu, Hawaii.

Several mTOR inhibitors have already been approved for therapeutic use, in particular in the treatment of cancer and allograft rejection.

Tissue - cultured corneal cells were used for in vitro studies rather than the usual lymphoid cells since corneal cells are the relevant target cells in vivo during corneal allograft rejection.

In the present study we sought to determine the role and mechanisms of CD4 - independent rejection of corneal allografts.

However, closer scrutiny of these studies raises questions about the role of CD4 + T cells as the sole mediators of corneal graft rejection, as corneal allografts undergo immune rejection in 33 % of the mice and 64 % of the rats treated with anti-CD4 monoclonal antibody (12, 13) and in 45 % of the CD4 KO mice (14).

Immunohistochemical staining of rejected human corneal allografts has revealed the presence of apoptosis in corneal stromal cells (5).

BALB / c corneal allografts underwent rejection in 46 % (6/13; MST = 46 days) of the recipients of CD8 − T lymphocytes and in 95 % (19/20; MST = 15 days) of the recipients of CD8 + T lymphocytes (Figure 2B).

The results of a typical experiment are shown in Figure 3 and demonstrate that even though spleen cells from CD4 KO mice could adoptively transfer corneal allograft rejection, they did not display conventional CTL activity against either BALB / c corneal epithelial or endothelial cells.

Although the immune basis for corneal allograft rejection was formally established in experimental animals by Maumenee (33) over 50 years ago, the exact immune mechanisms that lead to the corneal graft failure remain poorly understood.

The present findings are derived from studies using CD4KO mice and thus, raise the question as to whether the CD4 + T cell - independent immune mechanisms in CD4 KO mice differ from those involved in corneal allograft rejection in wild - type mice whose CD4 + T cells population have been depleted with monoclonal antibodies.

The role of DN T cells in corneal allograft rejection was confirmed in two separate in vitro assays in which CD8 − cells were isolated from CD4 KO donors that had rejected corneal allografts and were found to induce apoptosis of donor - specific corneal cells.

The combination of anti-NKG2D and CTLA - 4 Ig therapy prolongs islet allograft survival in a murine model.

Indeed, our results indicate that adoptive transfer of CD8 + T cells from CD4 KO mice that had rejected corneal allografts resulted in the rejection of 95 % of the corneal allografts transplanted to athymic recipients.

The capacity of CD8 + T cells to mediate corneal allograft rejection could have been due to the CTL population that might have been present in the CD8 + T cell suspensions used in the adoptive transfer inocula.

Several studies suggest that a significant number of corneal allografts undergo rejection in the absence of CD4 + T cells.

However, in vitro assays using spleen cells from CD4 KO mice that had rejected BALB / c corneal allografts failed to detect CTL activity against donor corneal epithelial or endothelial cells.

Current projects are investigating: 1) the expression of inflammatory genes during ischemia and reperfusion of kidneys during urology transplantation and in mouse models; 2) the expression of inflammatory genes and proteins in urine as markers indicating the presence of rejection in renal allografts; and 3) the role of adhesion molecules and chemokines in directing leukocyte infiltration into organ allografts.

In their study, DN T cells displayed allospecific cytotoxicity in vitro and mediated tumor allograft rejection in vivIn their study, DN T cells displayed allospecific cytotoxicity in vitro and mediated tumor allograft rejection in vivin vitro and mediated tumor allograft rejection in vivin vivo.

Overall, MSCs can exert protective effects in ischemic reperfusion injuries through anti-inflammatory and paracrine factors and this likely plays an important part in MSC enhancement of allograft survival.

The results indicated that 54 % (38/70) of the BALB / c corneal allografts underwent rejection in the CD4 KO hosts, while 100 % of the grafts were rejected in wild - type C57BL / 6 mice (Figure 1).

Additional adoptive transfer experiments were performed to ascertain the role of CD8 + and CD8 − T lymphocytes in CD4 - independent rejection of corneal allografts.

Insufficient or excess complement activation has been shown to be important in a wide range of disease states, such as multiple sclerosis, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and age - related macular degeneration, as well as in allograft rejection.

The results reported here reaffirm previous findings indicating that T cells are absolutely required for corneal allograft rejection in the mouse (3).

These findings also demonstrate the remarkable plasticity and redundancy in the immune mechanisms that mediate allograft rejection.

Spleen cells were isolated 7 — 14 days after C57BL / 6 CD4 KO mice had rejected BALB / c corneal allografts and were tested for anti - BALB / c CTL in a conventional 4 - hr 51Cr - release assay using BALB / c corneal epithelial and endothelial target cells.

Until recently, the dogma in transplantation immunology held that allograft rejection was a Th1 CD4 + cell - mediated process.

Experiments were performed to confirm that a significant number of corneal allografts underwent rejection in the absence of CD4 + T cells.

They found out that pre-organ transplant infusion of MSC in 1 or 2 doses [on day - 7 and day - 1] induced a profound T cell hyporesponsiveness and prolonged B6C3 cardiac allograft survival.

Hepatocyte growth factor prevents the development of chronic allograft nephropathy in rats.

Interestingly, Azuma et al 167 showed that HGF treatment prevents chronic allograft nephropathy in rats.

Ge W et al 40 reported that MSCs could induce kidney allograft tolerance by inducing the generation of CD4 + CD25 + FoxP3 + Tregs in vivo.

We have also generated T - regs (CD4 + / 25high / 127low / --RRB- in vitro from donor AD - MSC and recipient peripheral blood mononuclear cells and these T - regs are infused in thymus of renal allograft recipients after kidney transplantation.

In addition, infusion of recipient - derived B6 MSC tolerized a semiallogeneic B6C3 cardiac allograft, but not a fully MHC - mismatched BALB / c graft, and expanded Treg.